^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Gastric Cancer
    Drug:Jemperli (dostarlimab-gxly) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    10/06/2021
    Excerpt:
    Gastric cancer…Second-Line or Subsequent Therapy; Useful in Certain Circumstances...Dostarlimab-gxly for MSI-H or dMMR tumors was added
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Solid Tumor)
    New
    Excerpt:
    JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced...solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study

    Excerpt:
    ...Tumor status confirmed to be dMMR/MSI...
    Trial ID:
    DEWI